The Efficacy and Safety of Empagliflozin - Linagliptin and Empagliflozin- Metformin Therapy in Reduction of Body Weight in Type 2 Diabetic Patients .

Sponsor
Bahria University
Study ID
NCT07247656
Phase
PHASE4
Status
Completed

Conditions

  • Diabete Mellitus

Eligibility Criteria

Sex
ALL
Age
40 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The goal of this clinical trial is - Comparison of Empagliflozin - Linagliptin with Empagliflozin - Metformin combination therapy in reduction of body weight in T2DM Patients and it included 200 diabetic subjects with total study period of 12 weeks and individual study period of 4 weeks .

Key Dates

Start date
Dec 1, 2022
Status verified
Nov 2025
Primary completion
Mar 1, 2023
Completion
May 1, 2023

Study Design

Enrollment
200 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Group B received Empagliflozin with Linagliptin
    Empagliflozin 10 mg, along with Tab Linagliptin 5mg.
  • Active Comparator: Group A received Empagliflozin with Metformin
    Tab Empagliflozin 10 mg once daily, along with combination of Tab Metformin 500 mg

Primary Outcome Measure

Overall improvement in Fasting Blood Glucose [ Time Frame: 12 weeks ]

Related Studies